Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel

BACKGROUND: Treatment selection for men with metastatic castration-resistant prostate cancer (mCRPC) has become increasingly challenging with the introduction of novel therapies at earlier disease stages. The purpose of this study was to identify prognostic factors for overall survival (OS) and PSA...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Belderbos, Bodine P.S., de Wit, Ronald, Hoop, Esther Oomen-de, Nieuweboer, Annemieke, Hamberg, Paul, van Alphen, Robbert J., Bergman, André, van der Meer, Nelly, Bins, Sander, Mathijssen, Ron H.J., van Soest, Robert J.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739748/
https://ncbi.nlm.nih.gov/pubmed/29290963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22474
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados